Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by country, state, or city

Search by locations

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Japan”

A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum DisorderNot Yet Recruiting
NCT07285798Phase 3Updated Jun 30, 2026
Sponsor: Bristol-Myers Squibb
Irritability Associated With Autism Spectrum Disorder
United States, France, Germany, Hungary, India +4 more
A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of AgeActive Not Recruiting
NCT05399888Phase 2Updated Jun 30, 2026
Sponsor: Biogen
Mild Cognitive Impairment Due to Alzheimer's Disease · Alzheimer's Disease Dementia
United States, Australia, Belgium, Canada, Czechia +12 more
M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)Active Not Recruiting
NCT06421935Phase 1Updated Jun 30, 2026
Sponsor: EMD Serono Research & Development Institute, Inc.
Advanced Solid Tumor
United States, Australia, Japan, South Korea, Spain
The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula EdemaActive Not Recruiting
NCT06075147N/AUpdated Jun 30, 2026
Sponsor: Bayer
Visual Impairment · Neovascular Age-related Macular Degeneration (nAMD) · Diabetic Macula Edema (DME)
Australia, Canada, Denmark, Finland, France +13 more
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia ARecruiting
NCT05685238Phase 3Updated Jun 30, 2026
Sponsor: Novo Nordisk A/S
Haemophilia A · Haemophilia A With Inhibitors
United States, Austria, Belgium, Bulgaria, Canada +27 more
Phase 2b Study of GSK4532990 in Adults With NASHActive Not Recruiting
NCT05583344Phase 2Updated Jun 30, 2026
Sponsor: GlaxoSmithKline
Nonalcoholic Fatty Liver Disease · Non-alcoholic Fatty Liver Disease
United States, Argentina, Australia, Belgium, Canada +12 more
A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)Completed
NCT03600883Phase 1, Phase 2Updated Jun 30, 2026
Sponsor: Amgen
KRAS p.G12C Mutant Advanced Solid Tumors
United States, Australia, Austria, Belgium, Brazil +11 more
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder CancerRecruiting
NCT05951179Phase 2Updated Jun 30, 2026
Sponsor: Protara Therapeutics
Non-muscle Invasive Bladder Cancer
United States, Argentina, Brazil, Canada, Japan +1 more
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)Active Not Recruiting
NCT03924895Phase 3Updated Jun 30, 2026
Sponsor: Merck Sharp & Dohme LLC
Urinary Bladder Cancer, Muscle-invasive
United States, Argentina, Australia, Belgium, Canada +23 more
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid LeukemiaRecruiting
NCT04925479Phase 1, Phase 2Updated Jun 30, 2026
Sponsor: Novartis Pharmaceuticals
Myeloid Leukemia, Philadelphia Positive
United States, China, France, Germany, Greece +9 more
Safety and Efficacy Study of YZJ-1139 in Insomnia DisorderCompleted
NCT05525637Phase 3Updated Jun 30, 2026
Sponsor: Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Insomnia Disorder
China
Durability of Suppl. Rod Constructs-SuppleMentAry Rod Technique for Long-segment Posterior Instrumented Spinal FusionsRecruiting
NCT06368245N/AUpdated Jun 30, 2026
Sponsor: AO Foundation, AO Spine
Spinal Fusion
United States, Canada, China, India, Japan +2 more
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)Recruiting
NCT06947941Phase 3Updated Jun 30, 2026
Sponsor: Bristol-Myers Squibb
Alzheimer Disease · Psychosis
United States, Australia, Canada, Japan, United Kingdom
A Study of Navenibart in Participants With Hereditary AngioedemaActive Not Recruiting
NCT06842823Phase 3Updated Jun 30, 2026
Sponsor: Astria Therapeutics, Inc.
Hereditary Angioedema (HAE)
United States, Australia, Austria, Brazil, Bulgaria +19 more
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic DermatitisActive Not Recruiting
NCT07217015Phase 2Updated Jun 30, 2026
Sponsor: Kymera Therapeutics, Inc.
Atopic Dermatitis
United States, Australia, Canada, Czechia, Germany +3 more
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 DiabetesCompleted
NCT06010004Phase 3Updated Jun 30, 2026
Sponsor: Eli Lilly and Company
Type 2 Diabetes
Japan
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic LeukemiaActive Not Recruiting
NCT04994717Phase 3Updated Jun 30, 2026
Sponsor: Amgen
Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
United States, Australia, Austria, Belgium, Brazil +27 more
Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)Completed
NCT04609878Phase 3Updated Jun 30, 2026
Sponsor: AstraZeneca
Asthma
United States, Argentina, Belgium, Bulgaria, Canada +16 more
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver CancerCompleted
NCT00980460Phase 3Updated Jun 30, 2026
Sponsor: National Cancer Institute (NCI)
PRETEXT I Hepatoblastoma · PRETEXT II Hepatoblastoma · PRETEXT III Hepatoblastoma · PRETEXT IV Hepatoblastoma
United States, Australia, Brazil, Canada, Japan +1 more
Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast CancerRecruiting
NCT07604571Phase 1Updated Jun 30, 2026
Sponsor: Novartis Pharmaceuticals
Advanced HR+/HER2- Breast Cancer
United States, Japan, Singapore
Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)Completed
NCT04740307Phase 2Updated Jun 30, 2026
Sponsor: Merck Sharp & Dohme LLC
Advanced Hepatocellular Carcinoma
United States, China, Italy, Japan, Poland +4 more
A Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy)Recruiting
NCT07633301Phase 2Updated Jun 29, 2026
Sponsor: Takeda
Narcolepsy Type 1
United States, Australia, China, France, Italy +2 more
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 MutationActive Not Recruiting
NCT03173248Phase 3Updated Jun 29, 2026
Sponsor: Institut de Recherches Internationales Servier
Newly Diagnosed Acute Myeloid Leukemia (AML) · Untreated AML · AML Arising From Myelodysplastic Syndrome (MDS) · Leukemia, Myeloid, Acute
United States, Australia, Austria, Brazil, Canada +15 more
Avelumab Program Rollover StudyActive Not Recruiting
NCT03815643Phase 3Updated Jun 29, 2026
Sponsor: EMD Serono Research & Development Institute, Inc.
Solid Tumors
United States, Argentina, Australia, Belgium, Brazil +17 more
A Phase 2 Study of ONO-2808 in Patients With Multiple System AtrophyActive Not Recruiting
NCT05923866Phase 2Updated Jun 29, 2026
Sponsor: Ono Pharmaceutical Co., Ltd.
Multiple System Atrophy (MSA)
United States, Japan

Previous page Next page